<!DOCTYPE html>
<html lang="en" xml:lang="en">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 4 Sex disparity in liver allocation within Eurotransplant | Organ allocation models in Eurotransplant</title>
  <meta name="description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="generator" content="bookdown 0.42 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 4 Sex disparity in liver allocation within Eurotransplant | Organ allocation models in Eurotransplant" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/cover/thesis_cover.png" />
  <meta property="og:description" content="This is the PhD thesis of H.C. de Ferrante" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 4 Sex disparity in liver allocation within Eurotransplant | Organ allocation models in Eurotransplant" />
  
  <meta name="twitter:description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="twitter:image" content="/cover/thesis_cover.png" />

<meta name="author" content="Hans Christiaan de Ferrante" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="CHdynremeld.html"/>
<link rel="next" href="CHelassimulator.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="libs/kePrint-0.0.1/kePrint.js"></script>
<link href="libs/lightable-0.0.1/lightable.css" rel="stylesheet" />
<link href="libs/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
<script src="libs/bsTable-3.3.7/bootstrapTable.js"></script>



<style type="text/css">
  
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
</style>
<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="dankwoord.html"><a href="dankwoord.html"><i class="fa fa-check"></i>Dankwoord</a></li>
<li class="chapter" data-level="1" data-path="CHintroduction.html"><a href="CHintroduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="CHintroduction.html"><a href="CHintroduction.html#eurotransplant"><i class="fa fa-check"></i><b>1.1</b> Eurotransplant</a></li>
<li class="chapter" data-level="1.2" data-path="CHintroduction.html"><a href="CHintroduction.html#objective-medical-criteria-for-organ-allocation"><i class="fa fa-check"></i><b>1.2</b> Objective medical criteria for organ allocation</a></li>
<li class="chapter" data-level="1.3" data-path="CHintroduction.html"><a href="CHintroduction.html#fairness-in-organ-allocation"><i class="fa fa-check"></i><b>1.3</b> Fairness in organ allocation</a></li>
<li class="chapter" data-level="1.4" data-path="CHintroduction.html"><a href="CHintroduction.html#challenges-in-improving-organ-allocation-systems"><i class="fa fa-check"></i><b>1.4</b> Challenges in improving organ allocation systems</a></li>
<li class="chapter" data-level="1.5" data-path="CHintroduction.html"><a href="CHintroduction.html#outline-of-this-thesis"><i class="fa fa-check"></i><b>1.5</b> Outline of this thesis</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html"><i class="fa fa-check"></i><b>2</b> Liver allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="2.1" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#liver-allocation-prior-to-meld"><i class="fa fa-check"></i><b>2.1</b> Liver allocation prior to MELD</a></li>
<li class="chapter" data-level="2.2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-the-united-states"><i class="fa fa-check"></i><b>2.2</b> MELD-based liver allocation in the United States</a></li>
<li class="chapter" data-level="2.3" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-eurotransplant"><i class="fa fa-check"></i><b>2.3</b> MELD-based liver allocation in Eurotransplant</a></li>
<li class="chapter" data-level="2.4" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#areas-for-improvement-in-meld-based-allocation-systems"><i class="fa fa-check"></i><b>2.4</b> Areas for improvement in MELD-based allocation systems</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="CHdynremeld.html"><a href="CHdynremeld.html"><i class="fa fa-check"></i><b>3</b> Revising MELD from calendar-time cross-sections with correction for selection bias</a>
<ul>
<li class="chapter" data-level="3.1" data-path="CHdynremeld.html"><a href="CHdynremeld.html#introduction"><i class="fa fa-check"></i><b>3.1</b> Introduction</a></li>
<li class="chapter" data-level="3.2" data-path="CHdynremeld.html"><a href="CHdynremeld.html#materials-and-methods"><i class="fa fa-check"></i><b>3.2</b> Materials and methods</a></li>
<li class="chapter" data-level="3.3" data-path="CHdynremeld.html"><a href="CHdynremeld.html#results"><i class="fa fa-check"></i><b>3.3</b> Results</a></li>
<li class="chapter" data-level="3.4" data-path="CHdynremeld.html"><a href="CHdynremeld.html#discussion"><i class="fa fa-check"></i><b>3.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html"><i class="fa fa-check"></i><b>4</b> Sex disparity in liver allocation within Eurotransplant</a>
<ul>
<li class="chapter" data-level="4.1" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#introduction-1"><i class="fa fa-check"></i><b>4.1</b> Introduction</a></li>
<li class="chapter" data-level="4.2" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#materials-and-methods-1"><i class="fa fa-check"></i><b>4.2</b> Materials and methods</a></li>
<li class="chapter" data-level="4.3" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#results-1"><i class="fa fa-check"></i><b>4.3</b> Results</a></li>
<li class="chapter" data-level="4.4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#discussion-1"><i class="fa fa-check"></i><b>4.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="CHelassimulator.html"><a href="CHelassimulator.html"><i class="fa fa-check"></i><b>5</b> The ELAS simulator</a>
<ul>
<li class="chapter" data-level="5.1" data-path="CHelassimulator.html"><a href="CHelassimulator.html#introduction-2"><i class="fa fa-check"></i><b>5.1</b> Introduction</a></li>
<li class="chapter" data-level="5.2" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elassystem"><i class="fa fa-check"></i><b>5.2</b> The Eurotransplant Liver Allocation System (ELAS)</a></li>
<li class="chapter" data-level="5.3" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasdesign"><i class="fa fa-check"></i><b>5.3</b> The design of the ELAS simulator</a></li>
<li class="chapter" data-level="5.4" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasmodules"><i class="fa fa-check"></i><b>5.4</b> Modules of the ELAS simulator</a></li>
<li class="chapter" data-level="5.5" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasvv"><i class="fa fa-check"></i><b>5.5</b> Verification and validation</a></li>
<li class="chapter" data-level="5.6" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elascasestudies"><i class="fa fa-check"></i><b>5.6</b> Case studies: the impact of modifying ELAS rules</a></li>
<li class="chapter" data-level="5.7" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasconclusion"><i class="fa fa-check"></i><b>5.7</b> Conclusions and discussion</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html"><i class="fa fa-check"></i><b>6</b> Kidney allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="6.1" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#hla-matching-versus-fairness"><i class="fa fa-check"></i><b>6.1</b> HLA matching versus fairness</a></li>
<li class="chapter" data-level="6.2" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#kidney-allocation-programs-in-eurotransplant"><i class="fa fa-check"></i><b>6.2</b> Kidney allocation programs in Eurotransplant</a></li>
<li class="chapter" data-level="6.3" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#contemporary-challenges-in-kidney-allocation"><i class="fa fa-check"></i><b>6.3</b> Contemporary challenges in kidney allocation</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="CHvpra.html"><a href="CHvpra.html"><i class="fa fa-check"></i><b>7</b> Access to transplantation for immunized candidates</a>
<ul>
<li class="chapter" data-level="7.1" data-path="CHvpra.html"><a href="CHvpra.html#introduction-3"><i class="fa fa-check"></i><b>7.1</b> Introduction</a></li>
<li class="chapter" data-level="7.2" data-path="CHvpra.html"><a href="CHvpra.html#materials-and-methods-2"><i class="fa fa-check"></i><b>7.2</b> Materials and methods</a></li>
<li class="chapter" data-level="7.3" data-path="CHvpra.html"><a href="CHvpra.html#results-2"><i class="fa fa-check"></i><b>7.3</b> Results</a></li>
<li class="chapter" data-level="7.4" data-path="CHvpra.html"><a href="CHvpra.html#discussion-2"><i class="fa fa-check"></i><b>7.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html"><i class="fa fa-check"></i><b>8</b> The ETKidney simulator</a>
<ul>
<li class="chapter" data-level="8.1" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#introduction-4"><i class="fa fa-check"></i><b>8.1</b> Introduction</a></li>
<li class="chapter" data-level="8.2" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyalloc"><i class="fa fa-check"></i><b>8.2</b> The kidney allocation programs of Eurotransplant</a></li>
<li class="chapter" data-level="8.3" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydesign"><i class="fa fa-check"></i><b>8.3</b> Purpose and design of the ETKidney Simulator</a></li>
<li class="chapter" data-level="8.4" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneymodules"><i class="fa fa-check"></i><b>8.4</b> Modules of the ETKidney simulator</a></li>
<li class="chapter" data-level="8.5" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyvv"><i class="fa fa-check"></i><b>8.5</b> Verification and validation</a></li>
<li class="chapter" data-level="8.6" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneycasestudies"><i class="fa fa-check"></i><b>8.6</b> Case studies</a></li>
<li class="chapter" data-level="8.7" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydiscussion"><i class="fa fa-check"></i><b>8.7</b> Discussion and conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="CHdiscussion.html"><a href="CHdiscussion.html"><i class="fa fa-check"></i><b>9</b> The way forward</a>
<ul>
<li class="chapter" data-level="9.1" data-path="CHdiscussion.html"><a href="CHdiscussion.html#this-thesis-is-a-sharp-look-at-familiar-problems"><i class="fa fa-check"></i><b>9.1</b> This thesis is a sharp look at familiar problems</a></li>
<li class="chapter" data-level="9.2" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-to-look-beyond-survival-models-for-allocation"><i class="fa fa-check"></i><b>9.2</b> We need to look beyond survival models for allocation</a></li>
<li class="chapter" data-level="9.3" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-should-look-beyond-aggregate-outcomes"><i class="fa fa-check"></i><b>9.3</b> We should look beyond aggregate outcomes</a></li>
<li class="chapter" data-level="9.4" data-path="CHdiscussion.html"><a href="CHdiscussion.html#scientific-evidence-is-rarely-the-bottleneck"><i class="fa fa-check"></i><b>9.4</b> Scientific evidence is rarely the bottleneck</a></li>
<li class="chapter" data-level="9.5" data-path="CHdiscussion.html"><a href="CHdiscussion.html#the-chicken-and-egg-problem-in-allocation-development"><i class="fa fa-check"></i><b>9.5</b> The “chicken-and-egg” problem in allocation development</a></li>
<li class="chapter" data-level="9.6" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-more-constructive-dialogue"><i class="fa fa-check"></i><b>9.6</b> We need more constructive dialogue</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="APPipcw.html"><a href="APPipcw.html"><i class="fa fa-check"></i><b>A</b> Inverse Probability Censoring Weights</a>
<ul>
<li class="chapter" data-level="" data-path="APPipcw.html"><a href="APPipcw.html#definition-of-ipcw-weights"><i class="fa fa-check"></i>Definition of IPCW weights</a></li>
</ul></li>
<li class="chapter" data-level="B" data-path="APPimputation.html"><a href="APPimputation.html"><i class="fa fa-check"></i><b>B</b> Completing the status updates streams for transplant recipients</a>
<ul>
<li class="chapter" data-level="B.1" data-path="APPimputation.html"><a href="APPimputation.html#step-1-and-2-construction-of-the-pseudo-observations"><i class="fa fa-check"></i><b>B.1</b> Step 1 and 2: Construction of the pseudo-observations</a></li>
<li class="chapter" data-level="B.2" data-path="APPimputation.html"><a href="APPimputation.html#step-3-fitting-a-model-for-the-mean-restricted-survival-time"><i class="fa fa-check"></i><b>B.2</b> Step 3: Fitting a model for the mean restricted survival time</a></li>
<li class="chapter" data-level="B.3" data-path="APPimputation.html"><a href="APPimputation.html#step-4-constructing-future-statuses"><i class="fa fa-check"></i><b>B.3</b> Step 4: Constructing future statuses</a></li>
<li class="chapter" data-level="B.4" data-path="APPimputation.html"><a href="APPimputation.html#step-4.2-matching-the-patient-to-a-particular-patient-in-the-risk-set"><i class="fa fa-check"></i><b>B.4</b> Step 4.2: matching the patient to a particular patient in the risk set</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="course-of-life.html"><a href="course-of-life.html"><i class="fa fa-check"></i>Course of Life</a></li>
<li class="chapter" data-level="" data-path="list-of-publications.html"><a href="list-of-publications.html"><i class="fa fa-check"></i>List of publications</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Organ allocation models in Eurotransplant</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="CHsexdisparity" class="section level1 hasAnchor" number="4">
<h1><span class="header-section-number">Chapter 4</span> Sex disparity in liver allocation within Eurotransplant<a href="CHsexdisparity.html#CHsexdisparity" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p></p>
<hr />
<p>
An article based on this chapter has appeared in <em>American Journal of Transplantation</em>, de Ferrante, H.C., De Rosner-van Rosmalen M., Smeulders, B.M.L., Vogelaar, S., Spieksma, F.C.R., 2025, <a href="https://doi.org/10.1016/j.ajt.2024.06.018">10.1016/j.ajt.2024.06.018</a> <span class="citation"><a href="#ref-deFerranteSexDisparityLiver2024">[64]</a></span></p>
<p>
</p>
<p><p><strong>Abstract</strong></p>
</p>
<p>On Eurotransplant’s liver waiting list, females are relatively more likely to
die than males, and they are relatively less likely to be transplanted. With adult
candidates listed for liver transplantation between 2007
and 2019 (n=21,170), we study whether such sex disparity
is inherent to the Model for End-Stage Liver Disease (MELD) scoring system,
or the indirect result of a small candidate body size limiting access to
transplantation. We use Cox proportional hazards models to quantify (i) the
direct effect of sex on waiting list mortality, independent of sex’s effect
through MELD scores, and (ii) the direct effect of sex on the transplant rate,
independent of the effect of sex through MELD and candidate body size. We find that
adjusted waiting list mortality hazard ratios for female sex are insignificant
(HR = 1.03, 95% CI: 0.88–1.20), which means that we lack indications that MELD
systematically underestimates the waiting list mortality rates for females.
transplant rates are estimated to be 25% lower for females than for males in unadjusted
analyses (HR = 0.74, 95% CI: 0.71–0.77), but hazard ratios become insignificant
after adjustment for mediators, most importantly candidate height
and weight (HR = 0.98, 95% CI: 0.93–1.04). Sex disparity in Eurotransplant
thus appears to be largely a consequence of the lower transplant rates for females,
which are explained by differences in body size between males and females.</p>
<p></p>
<p></p>
<div id="introduction-1" class="section level2 hasAnchor" number="4.1">
<h2><span class="header-section-number">4.1</span> Introduction<a href="CHsexdisparity.html#introduction-1" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Prior research has shown that females are disadvantaged
under MELD-based liver allocation compared to males <span class="citation"><a href="#ref-moylanDisparitiesLiverTransplantation2008">[38]</a>, <a href="#ref-mathurSexBasedDisparitiesLiver2011">[65]</a>, <a href="#ref-laiHeightContributesGender2010">[66]</a>, <a href="#ref-lockeQuantifyingSexBasedDisparities2020a">[67]</a></span>.
There are two leading
explanations for such sex disparity in MELD-based liver allocation <span class="citation"><a href="#ref-vernaTimeActionAddress2020">[68]</a></span>, which we refer to as the <em>“GFR hypothesis”</em> and the <em>“size mismatch hypothesis”</em>.</p>
<p>The GFR hypothesis proposes that MELD is biased against female candidates because
MELD is based on serum creatinine instead of glomerular filtration rates (GFR).
With the same serum creatinine level, the GFRs of females are lower than the GFRs
of males <span class="citation"><a href="#ref-cholongitasFemaleLiverTransplant2007">[69]</a></span>. MELD would therefore systematically
underestimate the 90-day mortality risks for females. The GFR hypothesis has
frequently been invoked to propose alternatives to MELD which replace serum
creatinine with sex-specific estimates
of the glomerular filtration rate <span class="citation"><a href="#ref-rodriguezPeralvarezDevelopmentValidationGenderEquity2023">[70]</a>, <a href="#ref-myersGenderRenalFunction2011">[71]</a>, <a href="#ref-asraniMELDGRAILNaGlomerularFiltration2020">[72]</a></span>. These
alternatives award one to three extra points on the MELD scale to female
liver transplant candidates <span class="citation"><a href="#ref-vernaTimeActionAddress2020">[68]</a>, <a href="#ref-waltercostaRevisingMELDScore2023">[73]</a>, <a href="#ref-cholongitasGenderDisparityMELD2011">[74]</a>, <a href="#ref-allenReducedAccessLiver2018">[75]</a></span>.</p>
<p>The second hypothesis relates to donor-recipient size matching in liver transplantation.
Such size matching is crucial in liver transplantation because
(i) the liver must anatomically fit within the recipient’s abdominal cavity,
and (ii) the liver has to meet the candidate’s metabolic demands. The size-mismatch
hypothesis suggests that transplant candidates with a smaller stature
– who are predominantly female – are disadvantaged in MELD-based liver
allocation because donor-recipient size mismatch would require them to turn down
liver offers more frequently. This size mismatch hypothesis has received less
attention in the literature than the GFR hypothesis. Empirical evidence for
it comes from Lai et al. (2010), who showed that the lower transplant rates
for females in the United States are largely
explained by differences in candidate height <span class="citation"><a href="#ref-laiHeightContributesGender2010">[66]</a></span>.
Further evidence comes from Allen et al. (2018), who showed with competing risk
analyses that height indirectly explains most of the increased waiting list
deaths observed in female candidates <span class="citation"><a href="#ref-allenReducedAccessLiver2018">[75]</a></span>. A 2023
study by Sneiders et al. on retrospective data from Eurotransplant has also linked
a low body weight to adverse liver waiting list outcomes <span class="citation"><a href="#ref-Sneiders2023">[76]</a></span>.</p>
<p>In this chapter, we use causal mediation analysis to study the GFR hypothesis and the size mismatch hypothesis. A first
goal is to study whether there is evidence of a direct effect of sex on the
waiting list mortality rate, independently from MELD, as is implied by the
GFR hypothesis. A second goal is to quantify sex disparities in transplantation
rates, and to assess whether such disparities are mediated by
candidate body size – as is implied by the size mismatch hypothesis. To address
these research questions, we use retrospective data from Eurotransplant.</p>
<p>
</p>
</div>
<div id="materials-and-methods-1" class="section level2 hasAnchor" number="4.2">
<h2><span class="header-section-number">4.2</span> Materials and methods<a href="CHsexdisparity.html#materials-and-methods-1" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<div id="study-population" class="section level3 hasAnchor" number="4.2.1">
<h3><span class="header-section-number">4.2.1</span> Study population<a href="CHsexdisparity.html#study-population" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Candidates who were activated on the liver waiting list
between January 1, 2007 and December 31, 2019, were considered for inclusion.
We study sex disparity in two subpopulations. The first subpopulation consists
of candidates with common chronic indications for liver
transplantation. This population was obtained by excluding pediatric candidates
(16 years), candidates with rare metabolic diseases or rare exceptions
(awarded 15 times per year), those with acute liver failure, and
those waiting for a living donor transplantation, a repeat liver transplantation,
or a multi-organ transplantation. The second subpopulation consists of candidates
with cirrhosis who did not have HCC, which is the patient group
for which MELD was originally developed and validated <span class="citation"><a href="#ref-kamathModelPredictSurvival2001">[34]</a></span>.
This population was obtained by additionally excluding patients with exception points,
cholestatic liver disease, polycystic liver disease, and hepatocellular carcinoma.
We refer to this second population as “non-HCC candidates with cirrhosis”.</p>
</div>
<div id="meld-scores" class="section level3 hasAnchor" number="4.2.2">
<h3><span class="header-section-number">4.2.2</span> MELD scores<a href="CHsexdisparity.html#meld-scores" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Liver allocation in Eurotransplant is based on match-MELD scores, i.e., the
maximum of a candidate’s lab-MELD score (UNOS-MELD) and their exception scores.
Exception scores can be obtained for candidates with specific indications
who meet predefined eligibility criteria (standardized exceptions, SEs), or
through case-by-case review from national audit groups (non-standardized
exceptions, NSEs). Granted exceptions award an initial 90-day mortality
equivalent. The awarded mortality equivalents increase with every 90 days
of waiting time for most exceptions. For this study, candidates
with five types of exceptions were included: hepatocellular carcinoma (HCC),
polycystic liver disease, biliary sepsis, primary sclerosing cholangitis,
and NSEs. Other exceptions were excluded and are awarded, on average, less
than 15 times per year. The amount of points awarded for these exceptions varies by
country, and they can be found in the Eurotransplant liver manual <span class="citation"><a href="#ref-ETLiverMan2025">[58]</a></span>.</p>
<p>Several alternatives to UNOS-MELD have been proposed, which include MELD-Na,
ReMELD-Na and MELD 3.0. MELD 3.0 adds serum sodium, and was used for
liver allocation by UNOS from January 2016 to July 2023. ReMELD-Na
is a revision of MELD-Na on Eurotransplant registry data <span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>.
MELD 3.0 adds serum sodium, serum albumin and female sex to the MELD formula,
and was adopted for liver allocation by UNOS in July 2023. There are indications that
MELD-Na has exacerbated sex disparity <span class="citation"><a href="#ref-allenReducedAccessLiver2018">[75]</a></span>, while MELD
3.0 aims to rectify sex disparity by explicitly awarding points for female sex
<span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span>. This motivated us to also quantify sex disparity in mortality rates
for these three alternative scores.</p>
<p>Serum sodium and serum albumin are required to calculate these three MELD
alternatives. A problem is that values for these biomarkers are missing for
most candidates, as they were voluntarily reportable in Eurotransplant in the
study period. In this
chapter, main analyses for MELD-Na, ReMELD-Na and MELD 3.0 are done on subgroups
for whom the required biomarkers were available at listing (i.e., complete case analysis).
We compare this with multiple imputation (MI) as a sensitivity check.</p>
</div>
<div id="statistical-analyses" class="section level3 hasAnchor" number="4.2.3">
<h3><span class="header-section-number">4.2.3</span> Statistical analyses<a href="CHsexdisparity.html#statistical-analyses" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Mediation analysis is used to (i) quantify the total and the controlled direct
effect of sex on transplant rates (Section <a href="CHsexdisparity.html#CHmediationtxp">4.2.3.1</a>),
and (ii) to quantify the controlled direct effect of candidate sex on the
waiting list mortality rate, independent of MELD (Section <a href="CHsexdisparity.html#CHmediationmrt">4.2.3.2</a>).
For both analyses, directed acyclic graphs (DAGs) were constructed to guide
our modeling strategy and communicate visually our causal assumptions
<span class="citation"><a href="#ref-lipskyCausalDirectedAcyclic2022">[77]</a></span>.</p>
<div id="CHmediationtxp" class="section level4 hasAnchor" number="4.2.3.1">
<h4><span class="header-section-number">4.2.3.1</span> Mediation analysis for the transplant rate<a href="CHsexdisparity.html#CHmediationtxp" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>The left-hand side of Figure <a href="CHsexdisparity.html#fig:ch4fig1">4.1</a> shows the DAG for transplantation
analyses. In this model, sex is the exposure and
transplantation (TXP) is the outcome. The candidate’s MELD score and body size
(height or weight) both represent mediators of the relation between sex and transplantation.
MELD acts as a mediator because sex affects MELD through differences in serum creatinine
(as proposed by the GFR hypothesis), and MELD is used to prioritize candidates for
liver transplantation. Body size acts as a mediator, because sex influences height
and weight, and because having a smaller stature limits a candidate’s access
to transplantation due to size mismatch (the size mismatch hypothesis).</p>
<p>To identify the controlled direct effect of sex on transplantation, all back-door
paths from sex to transplantation must be blocked. Adjusting
for MELD and body size is not sufficient for this, because doing so can open
back-door paths via common causes of the mediators (MELD / body size)
and the outcome (transplantation). U1-type variables (see Figure <a href="CHsexdisparity.html#fig:ch4fig1">4.1</a>)
represent common causes of MELD and the transplant rate. These include
whether the candidate receives biweekly dialysis, their exception score, their age, and
their disease group, which affect both a candidate’s MELD score and their center’s
willingness to accept and transplant a liver offer. U2-type variables represent
common causes of a candidate’s body size and their transplant rate. Two
important U2-type variables are frailty (which is associated with a lower weight,
and a possible contraindication for liver transplant) and diabetes (which is
associated with a higher weight, and a possible contraindication).</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig1"></span>
<img src="figures/ch4/fig1_plot_causal_models.png" alt="Directed acyclic graphs (DAGs) for mediation analyses of the effect of sex on transplantation (TXP, left) and the effect of sex on pre-transplant mortality rates (MRT, right). Squares indicate the minimal sufficient adjustment set required to identify the controlled direct effect of sex on the outcome. U1, U2, and U3 represent common causes of the mediator-outcome relations. Dotted arrows indicate that sex is allowed to affect U1, U2, and U3; their presence or absence does not impact the identification of the controlled direct effect under our identification strategy." width="100%" />
<p class="caption">
Figure 4.1: Directed acyclic graphs (DAGs) for mediation analyses of the effect of sex on transplantation (TXP, left) and the effect of sex on pre-transplant mortality rates (MRT, right). Squares indicate the minimal sufficient adjustment set required to identify the controlled direct effect of sex on the outcome. U1, U2, and U3 represent common causes of the mediator-outcome relations. Dotted arrows indicate that sex is allowed to affect U1, U2, and U3; their presence or absence does not impact the identification of the controlled direct effect under our identification strategy.
</p>
</div>
<p>In principle, adjusting for MELD, body size, U1-type variables, and U2-type variables would
be sufficient to close all back-door paths. Unfortunately, frailty and diabetes (U2-type
variables) are not reported to Eurotransplant, which makes this adjustment strategy
infeasible. We instead assume that U2-type variables only affect the transplantation
rate through candidate eligibility (ELIG) for transplantation. Under this assumption,
we can alternatively identify the controlled direct effect of sex on transplantation
by adjusting for U1, MELD, size, and ELIG (time-varying variable).</p>
<p>We consider this assumption plausible for two reasons. Firstly, our patient
cohort is restricted to candidates who were actually activated
on the liver waiting list. Such waiting list activation represents a strong signal
that the candidate is deemed fit enough for transplantation by their center,
as frail or overweight candidates would be required to improve their health status
before waiting list activation (for example in consultation with a dietitian).
Secondly, in our experience, centers tend to report candidates who are temporarily
unavailable for transplantation because of a poor health status as non-transplantable
to Eurotransplant. Temporary non-transplantability (ELIG) is thus a strong proxy
for U2-type variables that is observed by Eurotransplant, and can be adjusted
for in our analysis.</p>
<p></p>
<p>To estimate the effects of sex on transplant rates, we use Cox proportional
hazards models which use time since waiting list activation as the timescale.
For quantification of the direct effect of sex on the transplant rate, we adjust
match-MELD, body size (height, weight, or both), and U1-type variables
(dialysis, type exception received, candidate age, and disease group / cirrhosis
etiology through stratification). Transplantation eligibility is explicitly controlled for
by adjusting for whether a candidate is temporarily non-transplantable
(NT), and implicitly controlled for by only including actively waiting listed
candidates in the analysis (which signals that the candidate is deemed eligible
for liver transplantation by the transplant center). In our analyses, we further
adjust for pure predictors of the transplantation
rate (country of listing through stratification, blood group, time spent non-transplantable).
The following variables are time-varying: primary disease group,
non-transplantable (NT) status, time spent NT (separately for too good / too bad / other), the match
MELD, type of exception, and receival of dialysis twice within a week before the last
reported lab-MELD score. Continuous variables are adjusted for with natural
cubic spline transformations with 4 degrees of freedom.</p>
<p>Three sensitivity checks are done. The first is to examine whether
there are sex-height and sex-weight interactions. This sensitivity check is motivated by
findings by Allen et al., who reported that the relation between candidate
height and the relative transplant rate differs significantly by candidate sex
in the United States <span class="citation"><a href="#ref-allenReducedAccessLiver2018">[75]</a></span>. The other sensitivity
checks are related to Eurotransplant-specific allocation mechanisms that give physicians freedom to
choose candidates for transplantation. Two such mechanisms are allocation
through extended allocation (15% of placements) and competitive rescue
allocation (10% of placements), which Eurotransplant jointly refers to as <em>non-standard</em>
allocation mechanisms. To rule out that sex disparities
are the result of physician preferences in non-standard allocation, we
repeat analyses with transplantation through standard allocation as
the outcome (our second sensitivity check). Another mechanism that
allows centers to freely choose a living waiting list candidate for transplantation
are center offers. As the third sensitivity check, we repeat the analysis on candidates listed in
countries without center offers (Germany and the Netherlands).</p>
</div>
<div id="CHmediationmrt" class="section level4 hasAnchor" number="4.2.3.2">
<h4><span class="header-section-number">4.2.3.2</span> Mediation analyses for the waiting list mortality rate<a href="CHsexdisparity.html#CHmediationmrt" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>The right-hand side of Figure <a href="CHsexdisparity.html#fig:ch4fig1">4.1</a> shows the DAG for mortality analyses.
Sex is the exposure, and waiting list mortality is the outcome. We are interested in the
controlled direct effect of sex on the mortality rate, not mediated by lab-MELD.
This requires control for sex, lab-MELD, and confounders of the relation between
lab-MELD and mortality (U3-type variables).
We estimate this direct effect of sex on mortality rates with Cox proportional
hazards models, with
adjustment for lab-MELD at listing (UNOS-MELD, MELD-Na, ReMELD-Na, or MELD 3.0) and
U3-type variables (disease group through
stratification, biweekly dialysis, candidate age, and type exception). Models are
additionally stratified by the candidate’s country of listing. Waiting list death is used as the outcome.
Candidates who died within 90 days of delisting are treated as a waiting list death.
Candidates still waiting 90 days after waiting list activation are censored,
as are candidates who were transplanted or delisted within 90 days of listing.</p>
<p>Several sensitivity checks are conducted. Firstly, we repeat the analyses in datasets
where serum sodium and albumin at listing were imputed with multiple imputation (MI).
Secondly, we compare to using death / removed unfit as a combined outcome.
Thirdly, Lai et al. reported that sex
disparity increased with renal dysfunction <span class="citation"><a href="#ref-laiHeightContributesGender2010">[66]</a></span>,
motivating us to repeat the analyses
in candidates with high MELD scores (MELD ≥18, 31% of candidates) and
elevated creatinine (≥1.0 mg/dl, 39% of candidates). Finally, to exclude
that impending waiting list deaths are prevented with center offers,
we repeat the analysis in Dutch and German candidates only.</p>
</div>
<div id="correction-for-dependent-censoring-in-mortality-analyses" class="section level4 hasAnchor" number="4.2.3.3">
<h4><span class="header-section-number">4.2.3.3</span> Correction for dependent censoring in mortality analyses<a href="CHsexdisparity.html#correction-for-dependent-censoring-in-mortality-analyses" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>The standard Cox PH model assumes that censoring is non-informative, which means
that conditional on covariates, censored candidates have similar expected
survival as non-censored candidates. In mortality analyses, candidates are censored
at transplantation while adjustment is for the MELD score reported at listing.
The non-informative censoring assumption then entails that transplanted candidates
and not (yet) transplanted candidates with the same MELD score at listing would face
similar mortality risks if they had remained on the waiting list.
This assumption is implausible for the Eurotransplant liver waiting list, as
Eurotransplant ranks candidates by their last reported MELD score and
not MELD at listing. Of the two candidates with the same
MELD score at listing, the candidate with a higher last reported MELD score would
thus face a higher mortality and higher transplant rate. In expectation,
transplanted candidates therefore have lower without-transplant survival than
non-transplanted candidates, which violates the non-informative censoring
assumption.</p>
<p>One can correct for this bias with inverse probability censoring weighting (IPCW),
as was previously applied in studying sex disparity by Wood et al. <span class="citation"><a href="#ref-woodCorrectingSexDisparity2021">[78]</a></span>. In this chapter, we use statistical methodology
developed by Gong and Schaubel to account for selection bias by transplantation <span class="citation"><a href="#ref-gongEstimatingAverageTreatment2017">[79]</a></span>. Details on this procedure are included
in Appendix <a href="APPipcw.html#APPipcw">A</a>. A sensitivity check is included to assess how IPCW
affects estimates of the direct effects of sex.</p>
</div>
<div id="multiple-imputation" class="section level4 hasAnchor" number="4.2.3.4">
<h4><span class="header-section-number">4.2.3.4</span> Multiple imputation<a href="CHsexdisparity.html#multiple-imputation" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>Multiple imputation is used as a sensitivity check in quantifying the direct
effect of sex on the waiting list mortality rate. For this, we used multiple
imputation with chained equations (MICE) to impute serum sodium and serum albumin values at
listing using predictive mean matching, constructing M=10 completed datasets.
After imputing serum sodium and albumin, MELD-Na, MELD 3.0, and ReMELD-Na were
calculated using the imputed values. We included the event indicator
and estimated baseline cumulative hazard in the imputation procedure, as
recommended by White et al. <span class="citation"><a href="#ref-whiteMultipleImputationUsing2011">[80]</a></span>.
MICE yields unbiased estimation of regression coefficients under a missing at
random (MAR) assumption. This assumption would be violated if a candidate’s actual serum sodium or albumin value influenced whether that value was available at Eurotransplant. Such a violation is implausible in our setting, as missingness arises almost entirely from center-level policies: some centers always report serum sodium and albumin to Eurotransplant, while other centers never report these biomarkers. The availability of these laboratory values is not determined by the candidate’s true biomarker level, but exclusively by their center’s reporting policy for serum sodium and albumin.</p>
</div>
</div>
</div>
<div id="results-1" class="section level2 hasAnchor" number="4.3">
<h2><span class="header-section-number">4.3</span> Results<a href="CHsexdisparity.html#results-1" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>This study considered 31,756 candidate listings for inclusion
(see Figure <a href="CHsexdisparity.html#fig:ch4fig2">4.2</a>). From these registrations, we excluded pediatric candidates (n=1,652), listings for repeat liver transplantation (n=3,865) or multi-organ transplantation (n=1,523),
candidates with acute liver failure or a High Urgency (HU) status (n=1,753), and candidates
with rare metabolic diseases or rare exceptions (n=755). The main cohort
consisted of 21,188 listings belonging to 21,170 candidates.</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig2"></span>
<img src="figures/ch4/fig2_flow_diagram.png" alt="Flow diagram for how the main study cohort and the subpopulation of non-HCC candidates with cirrhosis were selected from all candidates listed between January 1, 2007 and December 31, 2019." width="95%" />
<p class="caption">
Figure 4.2: Flow diagram for how the main study cohort and the subpopulation of non-HCC candidates with cirrhosis were selected from all candidates listed between January 1, 2007 and December 31, 2019.
</p>
</div>
<p></p>
<p>Table <a href="CHsexdisparity.html#tab:ch4tab1">4.1</a> describes the baseline characteristics of candidates included in the
main cohort, of which 6,597 (31%) are female and 14,573 (69%) are male. We
use standardized mean differences (SMD) to compare the distributions of baseline
variables across sexes, with SMD greater than 0.10 interpreted as meaningful imbalance.
On average, females are 2 years younger (SMD: 0.19),
12 cm shorter (SMD: 1.8) and 15 kg lighter (SMD: 1.0) than males. Females also
have on average 0.13 mg/dl lower serum creatinine at listing (SMD: 0.20) and
0.6 mg/dl higher bilirubin (SMD: 0.08). Despite these
differences, the calculated UNOS-MELD scores are similar
between the sexes (SMD: 0.00).
There is sex imbalance in etiologies of end-stage liver disease (SMD: 0.49), with
notably fewer females listed with HCC (11.8% of females compared to 21% of males). Relatively fewer females receive
exception points (SMD: 0.32).</p>
<p>
</p>
<table>
<caption>
<span id="tab:ch4tab1">Table 4.1: </span>Baseline characteristics of primary liver transplant candidates included in this study. For candidates with multiple listings only the first listing was used (n=118).
</caption>
<thead>
<tr>
<th style="text-align:left;">
variable
</th>
<th style="text-align:left;">
level
</th>
<th style="text-align:center;">
females<br>(n=6,597)
</th>
<th style="text-align:center;">
males<br>(n=14,573)
</th>
<th style="text-align:left;">
SMD
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="7">
disease group
</td>
<td style="text-align:left;">
cirrhosis
</td>
<td style="text-align:center;">
3,771 (57.2%)
</td>
<td style="text-align:center;">
7,976 (54.7%)
</td>
<td style="text-align:left;">
0.487
</td>
</tr>
<tr>
<td style="text-align:left;">
benign tumor or PLD
</td>
<td style="text-align:center;">
306 (4.6%)
</td>
<td style="text-align:center;">
62 (0.4%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
cancer
</td>
<td style="text-align:center;">
129 (2.0%)
</td>
<td style="text-align:center;">
172 (1.2%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
cholestatic
</td>
<td style="text-align:center;">
1,092 (16.6%)
</td>
<td style="text-align:center;">
1,350 (9.3%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
HCC
</td>
<td style="text-align:center;">
1,096 (16.6%)
</td>
<td style="text-align:center;">
4,654 (31.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
metabolic
</td>
<td style="text-align:center;">
72 (1.1%)
</td>
<td style="text-align:center;">
233 (1.6%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
other
</td>
<td style="text-align:center;">
131 (2.0%)
</td>
<td style="text-align:center;">
126 (0.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
exception at listing
</td>
<td style="text-align:left;">
cholestatic
</td>
<td style="text-align:center;">
163 (2.5%)
</td>
<td style="text-align:center;">
324 (2.2%)
</td>
<td style="text-align:left;">
0.318
</td>
</tr>
<tr>
<td style="text-align:left;">
HCC
</td>
<td style="text-align:center;">
780 (11.8%)
</td>
<td style="text-align:center;">
3,180 (21.8%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
NSE
</td>
<td style="text-align:center;">
115 (1.7%)
</td>
<td style="text-align:center;">
168 (1.2%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
PLD
</td>
<td style="text-align:center;">
127 (1.9%)
</td>
<td style="text-align:center;">
24 (0.2%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
none
</td>
<td style="text-align:center;">
5,412 (82.0%)
</td>
<td style="text-align:center;">
10,877 (74.6%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
match-MELD
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
16 [10-20]
</td>
<td style="text-align:center;">
16 [10-20]
</td>
<td style="text-align:left;">
0.002
</td>
</tr>
<tr>
<td style="text-align:left;">
lab-MELD
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
15.8 [9.7-19.6]
</td>
<td style="text-align:center;">
15.7 [10.2-18.8]
</td>
<td style="text-align:left;">
0.025
</td>
</tr>
<tr>
<td style="text-align:left;">
MELD-Na
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
17.4 [11.0-22.4]
</td>
<td style="text-align:center;">
17.4 [11.0-22.0]
</td>
<td style="text-align:left;">
0.007
</td>
</tr>
<tr>
<td style="text-align:left;">
ReMELD-Na
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
14.9 [9.3-19.4]
</td>
<td style="text-align:center;">
15.3 [10.3-19.3]
</td>
<td style="text-align:left;">
0.058
</td>
</tr>
<tr>
<td style="text-align:left;">
bilirubin (mg/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
5.51 [1.10-6.08]
</td>
<td style="text-align:center;">
4.87 [1.17-4.66]
</td>
<td style="text-align:left;">
0.083
</td>
</tr>
<tr>
<td style="text-align:left;">
creatinine (mg/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
1.00 [0.67-1.10]
</td>
<td style="text-align:center;">
1.13 [0.78-1.22]
</td>
<td style="text-align:left;">
0.200
</td>
</tr>
<tr>
<td style="text-align:left;">
INR
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
1.49 [1.13-1.60]
</td>
<td style="text-align:center;">
1.47 [1.17-1.60]
</td>
<td style="text-align:left;">
0.038
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
serum sodium (mmol/l)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
137 [134-140]
</td>
<td style="text-align:center;">
136 [134-140]
</td>
<td style="text-align:left;">
0.044
</td>
</tr>
<tr>
<td style="text-align:left;">
missing
</td>
<td style="text-align:center;">
4,238 (64.2%)
</td>
<td style="text-align:center;">
9,118 (62.6%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
serum albumin (g/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
3.3 [2.9-3.8]
</td>
<td style="text-align:center;">
3.3 [2.8-3.7]
</td>
<td style="text-align:left;">
0.073
</td>
</tr>
<tr>
<td style="text-align:left;">
missing
</td>
<td style="text-align:center;">
5,219 (79.1%)
</td>
<td style="text-align:center;">
11,502 (78.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
dialysis twice in the last week
</td>
<td style="text-align:left;">
</td>
<td style="text-align:center;">
171 (2.6%)
</td>
<td style="text-align:center;">
332 (2.3%)
</td>
<td style="text-align:left;">
0.020
</td>
</tr>
<tr>
<td style="text-align:left;">
candidate height (cm)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
165 [160-169]
</td>
<td style="text-align:center;">
177 [172-182]
</td>
<td style="text-align:left;">
1761
</td>
</tr>
<tr>
<td style="text-align:left;">
candidate weight (kg)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
69 [59-77]
</td>
<td style="text-align:center;">
84 [74-94]
</td>
<td style="text-align:left;">
1020
</td>
</tr>
<tr>
<td style="text-align:left;">
age at registration (years)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
53 [47-61]
</td>
<td style="text-align:center;">
55 [50-62]
</td>
<td style="text-align:left;">
0.185
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
exit reason (90 days)
</td>
<td style="text-align:left;">
transplanted
</td>
<td style="text-align:center;">
1,458 (22.1%)
</td>
<td style="text-align:center;">
4,266 (29.3%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
died
</td>
<td style="text-align:center;">
514 (7.8%)
</td>
<td style="text-align:center;">
979 (6.7%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
waiting
</td>
<td style="text-align:center;">
4,464 (67.7%)
</td>
<td style="text-align:center;">
8,927 (61.3%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
censored
</td>
<td style="text-align:center;">
82 (1.2%)
</td>
<td style="text-align:center;">
159 (1.1%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
removed
</td>
<td style="text-align:center;">
79 (1.2%)
</td>
<td style="text-align:center;">
242 (1.7%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
exit reason (1 year)
</td>
<td style="text-align:left;">
transplanted
</td>
<td style="text-align:center;">
2,764 (41.9%)
</td>
<td style="text-align:center;">
7,844 (53.8%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
died
</td>
<td style="text-align:center;">
904 (13.7%)
</td>
<td style="text-align:center;">
1,755 (12.0%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
waiting
</td>
<td style="text-align:center;">
2,381 (36.1%)
</td>
<td style="text-align:center;">
3,765 (25.8%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
censored
</td>
<td style="text-align:center;">
272 (4.1%)
</td>
<td style="text-align:center;">
419 (2.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
removed
</td>
<td style="text-align:center;">
276 (4.2%)
</td>
<td style="text-align:center;">
790 (5.4%)
</td>
<td style="text-align:left;">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> Abbreviations: </br>PLD, polycystic liver disease; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; NSE, non-standard exception; ReMELD-Na, refitted MELD-Na for Eurotransplant; SMD, standardized mean difference.
</td>
</tr>
</tfoot>
</table>
<p></p>
<p></p>
<p>In terms of outcomes, Table <a href="CHsexdisparity.html#tab:ch4tab1">4.1</a> shows that relatively fewer females
than males are transplanted 90 days after listing (22% vs. 29%), and relatively
more females die within 90 days of listing (7.8% vs. 6.7%). This sex disparity
has increased one year after listing, with only 41.9% of females transplanted compared to
53.8% of males, and 13.7% of female candidates having died on the waiting list
compared to 12.0% of males.</p>
<p>The cohort of non-HCC candidates with cirrhosis (n=11,342) was obtained by excluding
candidates with HCC (n=6,388), non-cirrhotic indications for liver
transplantation (n=3,426) or NSEs (n=96)
(see Figure <a href="CHsexdisparity.html#fig:ch4fig2">4.2</a>). Baseline characteristics of this subpopulation
are reported in Table <a href="CHsexdisparity.html#tab:ch4tab1cirrhotic">4.2</a>. Also among
this group, relatively fewer females are transplanted (26% vs. 32% of males) and
relatively more females die (10.5% vs. 9.8%) within 90 days of listing.</p>
<p>Figure <a href="CHsexdisparity.html#fig:ch4fig3">4.3</a> shows the distributions of the time spent by candidates on the waiting list
until waiting list exit (death, delisting, or transplantation), separately for exception
and non-exception patients. Whether or not they receive exception points, females
spend approximately 75 more days on the waiting list than males.</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig3"></span>
<img src="figures/ch4/fig3_waittime_at_exit.png" alt="Distributions of the time spent on the waiting list until waiting list exit (transplantation, death, or delisting), by sex and year of waiting list inclusion. The top panel shows waiting times for candidates with (non-)standard exceptions, the bottom panel for candidates without exceptions. Distributions were
  visualized with quantile dotplots, using 250 quantiles. The numbers displayed in the boxplots are the median number of days spent on the waiting list per group." width="100%" />
<p class="caption">
Figure 4.3: Distributions of the time spent on the waiting list until waiting list exit (transplantation, death, or delisting), by sex and year of waiting list inclusion. The top panel shows waiting times for candidates with (non-)standard exceptions, the bottom panel for candidates without exceptions. Distributions were
visualized with quantile dotplots, using 250 quantiles. The numbers displayed in the boxplots are the median number of days spent on the waiting list per group.
</p>
</div>
<p>
</p>
<table>
<caption>
<span id="tab:ch4tab1cirrhotic">Table 4.2: </span>Baseline characteristics for the subcohort of non-HCC candidates with cirrhosis.
</caption>
<thead>
<tr>
<th style="text-align:left;">
variable<br>
</th>
<th style="text-align:left;">
level<br>
</th>
<th style="text-align:center;">
females<br>(n=3,667)
</th>
<th style="text-align:center;">
males<br>(n=7,675)
</th>
<th style="text-align:center;">
SMD<br>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="6">
cirrhosis aetiology
</td>
<td style="text-align:left;">
alcoholic
</td>
<td style="text-align:center;">
1,686 (46.0%)
</td>
<td style="text-align:center;">
4,547 (59.2%)
</td>
<td style="text-align:center;">
0.37
</td>
</tr>
<tr>
<td style="text-align:left;">
autoimmune/cryptogenic
</td>
<td style="text-align:center;">
933 (25.4%)
</td>
<td style="text-align:center;">
961 (12.5%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
NAFLD<sup>a</sup>
</td>
<td style="text-align:center;">
189 (5.2%)
</td>
<td style="text-align:center;">
264 (3.4%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
hepatitis B
</td>
<td style="text-align:center;">
166 (4.5%)
</td>
<td style="text-align:center;">
435 (5.7%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
hepatitis C
</td>
<td style="text-align:center;">
438 (11.9%)
</td>
<td style="text-align:center;">
870 (11.3%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
metabolic/other/unknown
</td>
<td style="text-align:center;">
255 (7.0%)
</td>
<td style="text-align:center;">
598 (7.8%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
lab-MELD
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
18.5 [12.4-22.3]
</td>
<td style="text-align:center;">
18.5 [13.0-21.9]
</td>
<td style="text-align:center;">
0.005
</td>
</tr>
<tr>
<td style="text-align:left;">
MELD-Na
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
19.8 [13.9-24.7]
</td>
<td style="text-align:center;">
20.2 [14.8-24.5]
</td>
<td style="text-align:center;">
0.043
</td>
</tr>
<tr>
<td style="text-align:left;">
ReMELD-Na
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
17.2 [12.1-21.6]
</td>
<td style="text-align:center;">
17.9 [13.4-21.7]
</td>
<td style="text-align:center;">
0.100
</td>
</tr>
<tr>
<td style="text-align:left;">
bilirubin (mg/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
6.64 [1.64-7.56]
</td>
<td style="text-align:center;">
6.17 [1.70-6.20]
</td>
<td style="text-align:center;">
0.055
</td>
</tr>
<tr>
<td style="text-align:left;">
creatinine (mg/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
1.12 [0.71-1.26]
</td>
<td style="text-align:center;">
1.26 [0.81-1.40]
</td>
<td style="text-align:center;">
0.182
</td>
</tr>
<tr>
<td style="text-align:left;">
INR
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
1.66 [1.28-1.80]
</td>
<td style="text-align:center;">
1.63 [1.30-1.79]
</td>
<td style="text-align:center;">
0.037
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
serum sodium (mmol/l)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
136 [133-139]
</td>
<td style="text-align:center;">
135 [132-139]
</td>
<td style="text-align:center;">
0.102
</td>
</tr>
<tr>
<td style="text-align:left;">
missing
</td>
<td style="text-align:center;">
2,180 (59.4%)
</td>
<td style="text-align:center;">
4,398 (57.3%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
serum albumin (g/dl)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
3.2 [2.8-3.6]
</td>
<td style="text-align:center;">
3.2 [2.7-3.6]
</td>
<td style="text-align:center;">
0.099
</td>
</tr>
<tr>
<td style="text-align:left;">
missing
</td>
<td style="text-align:center;">
2,697 (73.5%)
</td>
<td style="text-align:center;">
5,512 (71.8%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
dialysis twice in last week
</td>
<td style="text-align:left;">
</td>
<td style="text-align:center;">
137 (3.7%)
</td>
<td style="text-align:center;">
262 (3.4%)
</td>
<td style="text-align:center;">
0.017
</td>
</tr>
<tr>
<td style="text-align:left;">
candidate height (cm)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
165 [160-169]
</td>
<td style="text-align:center;">
177 [172-182]
</td>
<td style="text-align:center;">
1809
</td>
</tr>
<tr>
<td style="text-align:left;">
candidate weight (kg)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
69 [59-77]
</td>
<td style="text-align:center;">
85 [74-95]
</td>
<td style="text-align:center;">
0.99
</td>
</tr>
<tr>
<td style="text-align:left;">
age at registration (years)
</td>
<td style="text-align:left;">
mean [Q1-Q3]
</td>
<td style="text-align:center;">
54 [48-61]
</td>
<td style="text-align:center;">
55 [49-61]
</td>
<td style="text-align:center;">
0.102
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
exit reason (90 days)
</td>
<td style="text-align:left;">
transplanted
</td>
<td style="text-align:center;">
947 (25.8%)
</td>
<td style="text-align:center;">
2,458 (32.0%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
died
</td>
<td style="text-align:center;">
380 (10.4%)
</td>
<td style="text-align:center;">
756 (9.9%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
waiting
</td>
<td style="text-align:center;">
2,272 (62.0%)
</td>
<td style="text-align:center;">
4,319 (56.3%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
censored
</td>
<td style="text-align:center;">
39 (1.1%)
</td>
<td style="text-align:center;">
75 (1.0%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
removed
</td>
<td style="text-align:center;">
29 (0.8%)
</td>
<td style="text-align:center;">
67 (0.9%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
exit reason (1 year)
</td>
<td style="text-align:left;">
transplanted
</td>
<td style="text-align:center;">
1,424 (38.8%)
</td>
<td style="text-align:center;">
3,851 (50.2%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
died
</td>
<td style="text-align:center;">
643 (17.5%)
</td>
<td style="text-align:center;">
1,290 (16.8%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
waiting
</td>
<td style="text-align:center;">
1,365 (37.2%)
</td>
<td style="text-align:center;">
2,149 (28.0%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
censored
</td>
<td style="text-align:center;">
126 (3.4%)
</td>
<td style="text-align:center;">
179 (2.3%)
</td>
<td style="text-align:center;">
</td>
</tr>
<tr>
<td style="text-align:left;">
removed
</td>
<td style="text-align:center;">
109 (3.0%)
</td>
<td style="text-align:center;">
206 (2.7%)
</td>
<td style="text-align:center;">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> <sup>a</sup>Many candidates with NAFLD have likely been registered under the autoimmune/cryptogenic disease code, as NAFLD could only be reported via free text during the study period.<br><b>Abbreviations:</b> NAFLD, non-alcoholic fatty liver disease; MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; ReMELD-Na, refitted MELD-Na for Eurotransplant; SMD, standardized mean difference.
</td>
</tr>
</tfoot>
</table>
<p>
</p>
<div id="CHrsltsmediationtxp" class="section level3 hasAnchor" number="4.3.1">
<h3><span class="header-section-number">4.3.1</span> Transplantation analyses<a href="CHsexdisparity.html#CHrsltsmediationtxp" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Figure <a href="CHsexdisparity.html#fig:ch4fig4">4.4</a> shows the estimated transplantation hazard ratios (HRs)
for female sex. The unadjusted effect of sex in the full cohort (top panel) suggest that the
transplant rates are approximately 25% lower for females
(HR = 0.74, 95% CI: 0.71–0.76). When
adjusting for candidate body size (weight + height) plus confounders of the
mediator-outcome relations, no sex difference in transplant rates is
found (HR = 0.98, 95% CI: 0.93–1.04). Similar results are found in non-HCC
candidates with cirrhosis (bottom panel), with 22% lower transplant rates for females in total (HR = 0.78, 95% CI: 0.74–0.82) but no sex
difference in transplant rates when adjusting for body size,
MELD, and confounders of both mediator-outcome relations (HR = 1.00, 95% CI: 0.93–1.07).</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig4"></span>
<img src="figures/ch4/fig4_hr_txp.png" alt="Estimates for the transplantation hazard ratios for female sex with 95\% confidence intervals, in the full cohort (top panel) and the subpopulation of non-HCC candidates with cirrhosis (bottom panel)." width="100%" />
<p class="caption">
Figure 4.4: Estimates for the transplantation hazard ratios for female sex with 95% confidence intervals, in the full cohort (top panel) and the subpopulation of non-HCC candidates with cirrhosis (bottom panel).
</p>
</div>
<p></p>
<p>Table <a href="CHsexdisparity.html#tab:ch4tab2">4.3</a> shows the results of sensitivity checks for this analysis.
The results are qualitatively similar when using transplantation through standard
allocation as the outcome (first row), and when estimating transplantation hazard
ratios in the countries without center offers (second row); in both cases,
the estimated hazard ratios are non-significant after
adjustment for mediators and confounders of the mediator-outcome relation.
Figure <a href="CHsexdisparity.html#fig:ch4fig5">4.5</a> shows
estimated spline terms for the relation between the relative transplantation
rate and height or weight, separately for males and females. For both sexes,
a lower height or weight is associated with a reduced transplant rate.
Height-sex (p=0.48) and weight-sex (p=0.11) interactions are insignificant in
ANOVA tests.</p>
<table class="table table-striped" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch4tab2">Table 4.3: </span>Sensitivity checks for the transplantation hazard ratio of female sex. Numbers in square brackets are 95% confidence intervals.
</caption>
<thead>
<tr>
<th style="text-align:left;">
sensitivity check
</th>
<th style="text-align:left;">
unadjusted effect of sex (total effect)
</th>
<th style="text-align:left;">
adjusted <span class="math inline">\(^a\)</span> + height and weight (direct effect of sex)
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
full cohort, non-rescue transplantation as the outcome
</td>
<td style="text-align:left;">
0.783 [0.749-0.819]
</td>
<td style="text-align:left;">
0.991 [0.930-1.055]
</td>
</tr>
<tr>
<td style="text-align:left;">
full cohort restricted to Germany and the Netherlands (no center offers)
</td>
<td style="text-align:left;">
0.735 [0.700-0.772]
</td>
<td style="text-align:left;">
0.962 [0.994-1.066]
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>a</sup> Variables adjusted for are the following: match-MELD, disease group, biweekly dialysis, type of (non) standardized exception received, candidate blood group, candidate age, and time spent non-transplantable.
</td>
</tr>
</tfoot>
</table>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig5"></span>
<img src="figures/ch4/fig5_size_sex_interactions.png" alt="Estimated relations between candidate height and the relative transplant rate, and candidate weight and the relative transplant rate, separately for males and females. These relations were estimated with cubic spline terms with 4 degrees of freedom." width="100%" />
<p class="caption">
Figure 4.5: Estimated relations between candidate height and the relative transplant rate, and candidate weight and the relative transplant rate, separately for males and females. These relations were estimated with cubic spline terms with 4 degrees of freedom.
</p>
</div>
</div>
<div id="CHrsltsmediationmrt" class="section level3 hasAnchor" number="4.3.2">
<h3><span class="header-section-number">4.3.2</span> Waiting list mortality analyses<a href="CHsexdisparity.html#CHrsltsmediationmrt" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Figure <a href="CHsexdisparity.html#fig:ch4fig6">4.6</a> shows estimates of the mortality hazard ratios for
female sex, adjusting for the lab-MELD score and confounders of the relation
between lab-MELD and the waiting list mortality rate. The waiting list mortality
hazard ratios include unity when adjusting for UNOS-MELD, both in the entire
cohort (HR = 1.03, 95% CI: 0.88–1.20) and in non-HCC candidates with cirrhosis
(HR 0.94, 95% CI: 0.80–1.11). Point estimates appear slightly increased for
MELD-Na and ReMELD-Na and decreased for MELD 3.0 (but confidence intervals include the null).</p>
<p>Table <a href="CHsexdisparity.html#tab:ch4tab3">4.4</a> reports sensitivity checks for these results. With multiple imputation (MI), point estimates for MELD-Na, ReMELD-Na and MELD 3.0 are closer to the null. For MELD 3.0, the estimated hazard ratios become statistically significant, both in the full cohort (HR = 0.83, 95% CI: 0.71–0.97) and in non-HCC candidates with cirrhosis (HR = 0.77, 95% CI: 0.66–0.91). Results are similar when using waiting list death / removed unfit as a joint outcome (third row). Point estimates are slightly increased in candidates with high UNOS-MELD scores or
elevated creatinine, but remain statistically insignificant (except for ReMELD-Na in high-MELD candidates, 95% CI: 1.02–1.59, fourth row). Results change little when estimated in Germany and the Netherlands, the Eurotransplant member countries without center offers (sixth row). Not correcting for dependent censoring with IPCW also appears to slightly increase point estimates.</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4fig6"></span>
<img src="figures/ch4/fig6_hr_mrt.png" alt="Estimates for waiting list mortality hazard ratios for female sex with 95\% confidence intervals, with adjustment for a lab-MELD score (UNOS-MELD, MELD-Na, ReMELD-Na or MELD 3.0) and confounders of the relation between lab-MELD and waiting list mortality." width="100%" />
<p class="caption">
Figure 4.6: Estimates for waiting list mortality hazard ratios for female sex with 95% confidence intervals, with adjustment for a lab-MELD score (UNOS-MELD, MELD-Na, ReMELD-Na or MELD 3.0) and confounders of the relation between lab-MELD and waiting list mortality.
</p>
</div>
<p>
</p>
<table class="table table-striped" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch4tab3">Table 4.4: </span>Sensitivity checks for the waiting list mortality analyses. Shown are the hazard ratios and 95% confidence intervals, estimated using IPCW with adjustment for MELD, and confounders of the relation between the MELD score and the transplant rate (candidate age, disease group, type exception and biweekly dialysis).
</caption>
<thead>
<tr>
<th style="text-align:left;">
sensitivity check
</th>
<th style="text-align:center;">
UNOS-MELD
</th>
<th style="text-align:center;">
MELD-Na
</th>
<th style="text-align:center;">
ReMELD-Na
</th>
<th style="text-align:center;">
MELD 3.0
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
full cohort, with MI
</td>
<td style="text-align:center;">
1.031 [0.885-1.200]
</td>
<td style="text-align:center;">
1.038 [0.895-1.204]
</td>
<td style="text-align:center;">
1.110 [0.958-1.285]
</td>
<td style="text-align:center;">
0.831 [0.715-0.966]
</td>
</tr>
<tr>
<td style="text-align:left;">
non-HCC candidates with cirrhosis, with MI
</td>
<td style="text-align:center;">
0.945 [0.804-1.111]
</td>
<td style="text-align:center;">
0.956 [0.817-1.120]
</td>
<td style="text-align:center;">
1.021 [0.872-1.196]
</td>
<td style="text-align:center;">
0.773 [0.658-0.907]
</td>
</tr>
<tr>
<td style="text-align:left;">
waitlist death or removed unfit as outcome
</td>
<td style="text-align:center;">
1.002 [0.864-1.162]
</td>
<td style="text-align:center;">
1.097 [0.874-1.376]
</td>
<td style="text-align:center;">
1.190 [0.981-1.443]
</td>
<td style="text-align:center;">
0.778 [0.589-1.028]
</td>
</tr>
<tr>
<td style="text-align:left;">
full cohort, MELD 18+
</td>
<td style="text-align:center;">
1.068 [0.908-1.257]
</td>
<td style="text-align:center;">
1.180 [0.920-1.513]
</td>
<td style="text-align:center;">
1.273 [1.022-1.587]
</td>
<td style="text-align:center;">
0.866 [0.632-1.187]
</td>
</tr>
<tr>
<td style="text-align:left;">
full cohort, creatinine<br> <span class="math inline">\(\geq\)</span> 1.0 mg/dl
</td>
<td style="text-align:center;">
1.118 [0.921-1.357]
</td>
<td style="text-align:center;">
1.199 [0.889-1.615]
</td>
<td style="text-align:center;">
1.249 [0.965-1.617]
</td>
<td style="text-align:center;">
0.745 [0.509-1.089]
</td>
</tr>
<tr>
<td style="text-align:left;">
recipient-driven countries
</td>
<td style="text-align:center;">
1.018 [0.847-1.224]
</td>
<td style="text-align:center;">
1.131 [0.832-1.539]
</td>
<td style="text-align:center;">
1.225 [0.948-1.583]
</td>
<td style="text-align:center;">
0.645 [0.427-0.974]
</td>
</tr>
<tr>
<td style="text-align:left;">
full cohort, no IPCW
</td>
<td style="text-align:center;">
1.097 [0.981-1.226]
</td>
<td style="text-align:center;">
1.182 [0.994-1.404]
</td>
<td style="text-align:center;">
1.226 [1.034-1.455]
</td>
<td style="text-align:center;">
0.898 [0.700-1.151]
</td>
</tr>
<tr>
<td style="text-align:left;">
non-HCC candidates with cirrhosis, no IPCW
</td>
<td style="text-align:center;">
1.034 [0.909-1.176]
</td>
<td style="text-align:center;">
1.098 [0.908-1.328]
</td>
<td style="text-align:center;">
1.135 [0.939-1.372]
</td>
<td style="text-align:center;">
0.837 [0.639-1.096]
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> Abbreviations: </br>HCC, hepatocellular carcinoma; IPCW, inverse probability censoring weighting; MELD, model for end-stage liver disease; MELD-Na, model for end-stage liver disease sodium; MI, multiple imputation; ReMELD-Na, refitted MELD-Na for Eurotransplant; UNOS, United Network for Organ Sharing.
</td>
</tr>
</tfoot>
</table>
<p></p>
<p></p>
</div>
<div id="liver-offer-acceptance-behavior" class="section level3 hasAnchor" number="4.3.3">
<h3><span class="header-section-number">4.3.3</span> Liver offer acceptance behavior<a href="CHsexdisparity.html#liver-offer-acceptance-behavior" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>To explore potential explanations for the reduced transplant rates among candidates
with a small stature, match lists generated between December 31, 2006
and December 31, 2019, were exported from the Eurotransplant database. Figure
<a href="CHsexdisparity.html#fig:ch4sfigsize">4.7</a>
shows the distributions of weights and heights for these match lists,
separately for candidates and donors. The plot shows that candidates and donors have broadly similar height and weight distributions, with considerable overlap. Figure <a href="CHsexdisparity.html#fig:ch4sfigoff">4.8</a> shows univariate
associations between graft offer acceptance and donor-candidate body size differences. The figure suggests
that size mismatch is indeed associated with declining
an organ offer. These associations are stronger if the
candidate weighs substantially lighter than the donor, or if the candidate is substantially
shorter.
</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4sfigsize"></span>
<img src="figures/ch4/size_distr.png" alt="Distributions of weights and heights for candidates and donors
  who appeared on Eurotransplant match lists between December 31, 2006 and December 31, 2019." width="75%" />
<p class="caption">
Figure 4.7: Distributions of weights and heights for candidates and donors
who appeared on Eurotransplant match lists between December 31, 2006 and December 31, 2019.
</p>
</div>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch4sfigoff"></span>
<img src="figures/ch4/sfig_univariate.png" alt="Univariate relations between the offer acceptance rate and the difference in donor and candidate body size, quantified through height or weight. These univariate relations were estimated with logistic models, using spline terms with 8 degrees of freedom." width="90%" />
<p class="caption">
Figure 4.8: Univariate relations between the offer acceptance rate and the difference in donor and candidate body size, quantified through height or weight. These univariate relations were estimated with logistic models, using spline terms with 8 degrees of freedom.
</p>
</div>
<p>
</p>
</div>
</div>
<div id="discussion-1" class="section level2 hasAnchor" number="4.4">
<h2><span class="header-section-number">4.4</span> Discussion<a href="CHsexdisparity.html#discussion-1" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>This chapter reports on sex disparity in liver waiting list outcomes in Eurotransplant.
Despite being listed at similar UNOS-MELD scores as males, relatively fewer females
are transplanted, and relatively more females die within 90 days of listing.
Similar results have been described in other geographic regions <span class="citation"><a href="#ref-moylanDisparitiesLiverTransplantation2008">[38]</a>, <a href="#ref-mathurSexBasedDisparitiesLiver2011">[65]</a>, <a href="#ref-laiHeightContributesGender2010">[66]</a>, <a href="#ref-lockeQuantifyingSexBasedDisparities2020a">[67]</a></span>.</p>
<p>We find that the transplant rates of females are approximately 25%
lower than those of males in Eurotransplant, both in the full cohort
and among non-HCC candidates with cirrhosis.
This disparity disappears when adjusting for candidate height and weight, with
the estimated 95% confidence intervals for the transplantation hazard ratio of
0.93–1.04 in the full cohort, and 0.93–1.07 in non-HCC candidates
with cirrhosis. Interactions of body
size with candidate sex are also insignificant, which suggests that small body
sizes are equally disadvantageous to males and females. We interpret these findings
as evidence for the size mismatch hypothesis: the smaller stature of female
candidates limits their chances of finding a suitable liver transplant, which results in sex disparity
in liver waiting list outcomes.</p>
<p>A potential explanation for the size mismatch hypothesis comes from the analysis
of the offer acceptance behavior of transplant centers: while weights and heights are similarly distributed in the donor
and patient populations, univariate analyses of offer acceptance
rates suggest that offers are more likely to be accepted for transplantation
when the donor has a similar or smaller body size than the patient. As a result,
there is high demand
for small organs, which disadvantages the small-statured patients who depend on
such offers for transplantation. Because these small-statured patients are predominantly
female, this also results in sex disparity.</p>
<p>Existing analyses from the United States have reported that females remain
disadvantaged after adjustment for age, height and weight, while our analyses
suggest that height and weight fully mediate the effect of sex on the transplantation
rate. This discrepancy could be explained by the fact that these existing
studies have adjusted for continuous variables either linearly
<span class="citation"><a href="#ref-mathurSexBasedDisparitiesLiver2011">[65]</a>, <a href="#ref-lockeQuantifyingSexBasedDisparities2020a">[67]</a></span> or with quantiles <span class="citation"><a href="#ref-laiHeightContributesGender2010">[66]</a>, <a href="#ref-nephewExceptionPointsBody2017">[81]</a></span>,
instead of with non-linear spline transformations. We find that such
adjustment strategies bias hazard ratios downwards (results not shown).</p>
<p>Regarding waiting list mortality rates, we find that the hazard ratios for female
sex include the null when adjusting for UNOS-MELD and relevant confounders,
both in the full cohort and in non-HCC candidates with cirrhosis. We thus find
no evidence that females face higher waiting list mortality rates than males when
at the same UNOS-MELD score. In other words, we find no evidence for the
GFR hypothesis in our main analyses.
</p>
<p>Studies from the United States have reported higher waiting list
mortality rates for females when adjusting for MELD or its biomarkers. For example, Moylan
et al. (2008) report a statistically significant hazard ratio of 1.09 for
female sex when adjusting for UNOS-MELD <span class="citation"><a href="#ref-moylanDisparitiesLiverTransplantation2008">[38]</a></span>,
Wood et al. (2021) report that without-transplant survival is 0 to 5
percentage lower for females with MELD-Na <span class="citation"><a href="#ref-woodCorrectingSexDisparity2021">[78]</a></span>, and
Kim et al. (2021) find a hazard ratio of 1.23 in developing MELD 3.0 <span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span>.
Compared to these estimates, the point estimates we obtained in the main analyses
with adjustment for UNOS-MELD are low (1.03 in the full cohort, and 0.94 in non-HCC candidates with cirrhosis).</p>
<p>Our sensitivity checks lead to several potential explanations for this discrepancy.
Firstly, candidates in the United States are sicker than
candidates in Eurotransplant,
with median MELD-Na scores at transplantation of 27 in OPTN <span class="citation"><a href="#ref-kwongOPTNSRTR20202022">[82]</a></span>
compared to 21 in Eurotransplant. We find that re-estimation of the mortality hazard
ratios in subgroups with higher MELD scores increases the estimated hazard ratio
for female sex slightly.
Secondly, 61% of our cohort has low creatinine (1.0 mg/dl). For these
candidates, a systematically lower creatinine for females would not translate into
lower MELD scores, because MELD scores are calculated with a lower limit of 1.0
mg/dl for creatinine. When we re-estimate waiting list mortality hazard ratios
in the 39% of candidates with elevated creatinine (≥1.0 mg/dl), the point
estimate increases to 1.12, which is more in line with existing literature
(although it remains statistically insignificant). We also find that not
correcting for dependent censoring by transplantation increases the point
estimates slightly.</p>
<p>A final difference is that our main results pertain to UNOS-MELD, whereas recent
studies adjust for scores which prioritize additionally on serum sodium (MELD-Na)
or serum sodium and serum albumin (MELD 3.0). With adjustment for
MELD-Na or ReMELD-Na instead of UNOS-MELD, our point estimates
of the waiting list mortality hazard ratio also increase to ±1.10 for MELD-Na
and ±1.20 for ReMELD-Na. They even become statistically significant in some
sensitivity checks for ReMELD-Na. These point estimates suggest
that the mortality rate of females is underestimated by 0.5 to 1 points on the MELD scale. When
adjusting for MELD 3.0 instead of UNOS-MELD, the point estimates for the mortality
hazard ratio are below 1. This suggests that the
1.33 extra points awarded to females in MELD 3.0 may overestimate the mortality
rates for females in Eurotransplant.</p>
<p>A clinical implication of our findings is that transplant centers should be aware of the
disadvantaged position of small-statured candidates when deciding whether to accept
a liver offer. Eurotransplant should also strive to rectify the sex disparity
that results from its current liver allocation algorithm. In the literature, the GFR hypothesis is frequently invoked
to motivate awarding points for female sex, either explicitly
<span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span> or indirectly by replacing creatinine in MELD by sex-specific
estimates of the GFR <span class="citation"><a href="#ref-rodriguezPeralvarezDevelopmentValidationGenderEquity2023">[70]</a>, <a href="#ref-myersGenderRenalFunction2011">[71]</a>, <a href="#ref-asraniMELDGRAILNaGlomerularFiltration2020">[72]</a></span>.
By awarding points to females, such scores reduce sex disparity. However,
they do not target a smaller stature, which represents the root cause of sex disparity
according to our analysis.
</p>
<p>A more efficient way of addressing sex disparity could involve giving extra priority
to small-statured candidates, regardless of their sex. We point out that such an
allocation score cannot be developed solely based on a Cox proportional hazards
model which uses waiting list death as the outcome and which adjusts for MELD biomarkers
and candidate height. The reason for this is that body size only indirectly results in waiting list
deaths by limiting the transplant rate of small-statured candidates. This
indirect mechanism is not captured when modeling the waiting
list mortality with Cox PH models; rectifying sex disparity due to the size
mismatch hypothesis will require a different approach.</p>
<p>One such approach could be to develop allocation scores with simulation, as is done
by Wood et al. <span class="citation"><a href="#ref-woodCorrectingSexDisparity2021">[78]</a></span>. A relevant proposal in this regard is a study by
Bernards et al., who assessed the effects of explicitly awarding points
to short candidates with Liver Simulation Allocation Model (LSAM) simulations
<span class="citation"><a href="#ref-bernardsAwardingAdditionalMELD2022">[83]</a></span>. They report that awarding 1 extra MELD point
to the 8% shortest waiting list candidates (156cm) is sufficient to result
in equalized outcomes across height groups in the United States. A similar
simulation study should be conducted for Eurotransplant, to assess how sex
disparity on the liver waiting list can be rectified.</p>
<p>Our study also has several limitations. Firstly, validity of the mediation analyses
depends on two unverifiable assumptions: no unmeasured confounding of mediator-outcome
relations, and the assumption that confounders of the body size-transplantation
rate act through candidate eligibility. Secondly, we rely on accuracy of
information in the Eurotransplant database. Thirdly, our quantifications of the direct
effect of sex on mortality are potentially underpowered when adjusting for
sodium-based MELD scores, as serum sodium is missing for most candidates in Eurotransplant registry
data. Fourthly, serum urea is not available in the Eurotransplant database such that
comparison to allocation scores which replace creatinine with estimated GFRs
was not possible.</p>
<p>In conclusion, this chapter has described sex disparities in liver waiting list
outcomes in Eurotransplant. In contrast to the existing literature, we lack
evidence that UNOS-MELD systematically underestimates pre-transplant
mortality rates in females. Our analysis instead suggests that transplantation
rates are lower in females because of their smaller stature. In addition to
externally validating MELD 3.0 and GEMA-Na, Eurotransplant should consider
prioritizing small-statured candidates to rectify sex disparity.</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body" entry-spacing="0">
<div id="ref-kimMELD3point0" class="csl-entry">
<div class="csl-left-margin">[20] </div><div class="csl-right-inline">W. R. Kim <em>et al.</em>, <span>“<span>MELD</span> 3.0: The <span class="nocase">Model for End-Stage Liver Disease</span> updated for the modern era,”</span> <em>Gastroenterology</em>, vol. 161, no. 6, pp. 1887–1895.e4, 2021, doi: <a href="https://doi.org/10.1053/j.gastro.2021.08.050">10.1053/j.gastro.2021.08.050</a>.</div>
</div>
<div id="ref-kamathModelPredictSurvival2001" class="csl-entry">
<div class="csl-left-margin">[34] </div><div class="csl-right-inline">P. S. Kamath <em>et al.</em>, <span>“A model to predict survival in patients with end-stage liver disease,”</span> <em>Hepatology</em>, vol. 33, no. 2, pp. 464–470, 2001, doi: <a href="https://doi.org/10.1053/jhep.2001.22172">10.1053/jhep.2001.22172</a>.</div>
</div>
<div id="ref-moylanDisparitiesLiverTransplantation2008" class="csl-entry">
<div class="csl-left-margin">[38] </div><div class="csl-right-inline">C. A. Moylan, C. W. Brady, J. L. Johnson, A. D. Smith, J. E. Tuttle-Newhall, and A. J. Muir, <span>“Disparities in liver transplantation before and after introduction of the <span>MELD</span> score,”</span> <em>JAMA</em>, vol. 300, no. 20, pp. 2371–2378, 2008, doi: <a href="https://doi.org/10.1001/jama.2008.720">10.1001/jama.2008.720</a>.</div>
</div>
<div id="ref-goudsmitRefittingModelEndstage2020" class="csl-entry">
<div class="csl-left-margin">[42] </div><div class="csl-right-inline">B. F. J. Goudsmit <em>et al.</em>, <span>“Refitting the <span class="nocase">Model for End-Stage Liver Disease</span> for the <span>Eurotransplant</span> region,”</span> <em>Hepatology</em>, 2020, doi: <a href="https://doi.org/10.1002/hep.31677">10.1002/hep.31677</a>.</div>
</div>
<div id="ref-ETLiverMan2025" class="csl-entry">
<div class="csl-left-margin">[58] </div><div class="csl-right-inline">Eurotransplant, <span>“<span>Eurotransplant Manual</span> manual. Chapter 4: <span>ET Liver Allocation System (ELAS)</span>.”</span> Available: <a href="https://www.eurotransplant.org/allocation/eurotransplant-manual/">https://www.eurotransplant.org/allocation/eurotransplant-manual/</a></div>
</div>
<div id="ref-deFerranteSexDisparityLiver2024" class="csl-entry">
<div class="csl-left-margin">[64] </div><div class="csl-right-inline">H. C. de Ferrante, M. de Rosner-van Rosmalen, B. M. L. Smeulders, S. Vogelaar, and F. C. R. Spieksma, <span>“Sex disparity in liver allocation within <span>Eurotransplant</span>,”</span> <em>American Journal of Transplantation</em>, vol. 25, no. 1, pp. 139–149, 2025, doi: <a href="https://doi.org/10.1016/j.ajt.2024.06.018">10.1016/j.ajt.2024.06.018</a>.</div>
</div>
<div id="ref-mathurSexBasedDisparitiesLiver2011" class="csl-entry">
<div class="csl-left-margin">[65] </div><div class="csl-right-inline">A. K. Mathur, D. E. Schaubel, Q. Gong, M. K. Guidinger, and R. M. Merion, <span>“Sex-based disparities in liver transplant rates in the <span>United States</span>,”</span> <em>American Journal of Transplantation</em>, vol. 11, no. 7, pp. 1435–1443, 2011, doi: <a href="https://doi.org/10.1111/j.1600-6143.2011.03498.x">10.1111/j.1600-6143.2011.03498.x</a>.</div>
</div>
<div id="ref-laiHeightContributesGender2010" class="csl-entry">
<div class="csl-left-margin">[66] </div><div class="csl-right-inline">J. C. Lai, N. A. Terrault, E. Vittinghoff, and S. W. Biggins, <span>“Height contributes to the gender difference in wait-list mortality under the <span class="nocase">MELD-based</span> liver allocation system,”</span> <em>American Journal of Transplantation</em>, vol. 10, no. 12, pp. 2658–2664, 2010, doi: <a href="https://doi.org/10.1111/j.1600-6143.2010.03326.x">10.1111/j.1600-6143.2010.03326.x</a>.</div>
</div>
<div id="ref-lockeQuantifyingSexBasedDisparities2020a" class="csl-entry">
<div class="csl-left-margin">[67] </div><div class="csl-right-inline">J. E. Locke <em>et al.</em>, <span>“Quantifying sex-based disparities in liver allocation,”</span> <em>JAMA Surgery</em>, vol. 155, no. 7, p. e201129, 2020, doi: <a href="https://doi.org/10.1001/jamasurg.2020.1129">10.1001/jamasurg.2020.1129</a>.</div>
</div>
<div id="ref-vernaTimeActionAddress2020" class="csl-entry">
<div class="csl-left-margin">[68] </div><div class="csl-right-inline">E. C. Verna and J. C. Lai, <span>“Time for action to address the persistent sex-based disparity in liver transplant access,”</span> <em>JAMA Surgery</em>, vol. 155, no. 7, p. 545, 2020, doi: <a href="https://doi.org/10.1001/jamasurg.2020.1126">10.1001/jamasurg.2020.1126</a>.</div>
</div>
<div id="ref-cholongitasFemaleLiverTransplant2007" class="csl-entry">
<div class="csl-left-margin">[69] </div><div class="csl-right-inline">E. Cholongitas <em>et al.</em>, <span>“Female liver transplant recipients with the same <span>GFR</span> as male recipients have lower <span>MELD</span> scores – a systematic bias,”</span> <em>American Journal of Transplantation</em>, vol. 7, no. 3, pp. 685–692, 2007, doi: <a href="https://doi.org/10.1111/j.1600-6143.2007.01666.x">10.1111/j.1600-6143.2007.01666.x</a>.</div>
</div>
<div id="ref-rodriguezPeralvarezDevelopmentValidationGenderEquity2023" class="csl-entry">
<div class="csl-left-margin">[70] </div><div class="csl-right-inline">M. L. Rodríguez-Perálvarez <em>et al.</em>, <span>“Development and validation of the gender-equity model for liver allocation <span>(GEMA)</span> to prioritise candidates for liver transplantation: A cohort study,”</span> <em>The Lancet. Gastroenterology &amp; Hepatology</em>, vol. 8, no. 3, pp. 242–252, 2023, doi: <a href="https://doi.org/10.1016/S2468-1253(22)00354-5">10.1016/S2468-1253(22)00354-5</a>.</div>
</div>
<div id="ref-myersGenderRenalFunction2011" class="csl-entry">
<div class="csl-left-margin">[71] </div><div class="csl-right-inline">R. P. Myers, A. A. M. Shaheen, A. I. Aspinall, R. R. Quinn, and K. W. Burak, <span>“Gender, renal function, and outcomes on the liver transplant waiting list: Assessment of revised <span>MELD</span> including estimated glomerular filtration rate,”</span> <em>Journal of Hepatology</em>, vol. 54, no. 3, pp. 462–470, 2011, doi: <a href="https://doi.org/10.1016/j.jhep.2010.07.015">10.1016/j.jhep.2010.07.015</a>.</div>
</div>
<div id="ref-asraniMELDGRAILNaGlomerularFiltration2020" class="csl-entry">
<div class="csl-left-margin">[72] </div><div class="csl-right-inline">S. K. Asrani <em>et al.</em>, <span>“<span>MELD-GRAIL-Na</span>: Glomerular filtration rate and mortality on liver-transplant waiting list,”</span> <em>Hepatology</em>, vol. 71, no. 5, pp. 1766–1774, 2020, doi: <a href="https://doi.org/10.1002/hep.30932">10.1002/hep.30932</a>.</div>
</div>
<div id="ref-waltercostaRevisingMELDScore2023" class="csl-entry">
<div class="csl-left-margin">[73] </div><div class="csl-right-inline">M. B. W. Costa, C. Gärtner, M. Schmidt, T. Berg, D. Seehofer, and T. Kaiser, <span>“Revising the <span>MELD</span> score to address sex-bias in liver transplant prioritization for a <span>German</span> cohort,”</span> <em>Journal of Personalized Medicine</em>, vol. 13, no. 6, p. 963, 2023, doi: <a href="https://doi.org/10.3390/jpm13060963">10.3390/jpm13060963</a>.</div>
</div>
<div id="ref-cholongitasGenderDisparityMELD2011" class="csl-entry">
<div class="csl-left-margin">[74] </div><div class="csl-right-inline">E. Cholongitas, M. Thomas, M. Senzolo, and A. K. Burroughs, <span>“Gender disparity and <span>MELD</span> in liver transplantation,”</span> <em>Journal of Hepatology</em>, vol. 55, no. 2, pp. 500–501, 2011, doi: <a href="https://doi.org/10.1016/j.jhep.2011.01.054">10.1016/j.jhep.2011.01.054</a>.</div>
</div>
<div id="ref-allenReducedAccessLiver2018" class="csl-entry">
<div class="csl-left-margin">[75] </div><div class="csl-right-inline">A. M. Allen <em>et al.</em>, <span>“Reduced access to liver transplantation in women: Role of height, <span>MELD</span> exception scores, and renal function underestimation,”</span> <em>Transplantation</em>, vol. 102, no. 10, pp. 1710–1716, 2018, doi: <a href="https://doi.org/10.1097/TP.0000000000002196">10.1097/TP.0000000000002196</a>.</div>
</div>
<div id="ref-Sneiders2023" class="csl-entry">
<div class="csl-left-margin">[76] </div><div class="csl-right-inline">D. Sneiders <em>et al.</em>, <span>“Quantifying the disadvantage of small recipient size on the liver transplantation waitlist, a longitudinal analysis within the <span>Eurotransplant</span> region,”</span> <em>Transplantation</em>, 2023, doi: <a href="https://doi.org/10.1097/tp.0000000000004804">10.1097/tp.0000000000004804</a>.</div>
</div>
<div id="ref-lipskyCausalDirectedAcyclic2022" class="csl-entry">
<div class="csl-left-margin">[77] </div><div class="csl-right-inline">A. M. Lipsky and S. Greenland, <span>“Causal directed acyclic graphs,”</span> <em>JAMA</em>, vol. 327, no. 11, pp. 1083–1084, 2022, doi: <a href="https://doi.org/10.1001/jama.2022.1816">10.1001/jama.2022.1816</a>.</div>
</div>
<div id="ref-woodCorrectingSexDisparity2021" class="csl-entry">
<div class="csl-left-margin">[78] </div><div class="csl-right-inline">N. L. Wood, D. VanDerwerken, D. L. Segev, and S. E. Gentry, <span>“Correcting the sex disparity in <span>MELD-Na</span>,”</span> <em>American Journal of Transplantation</em>, vol. 21, no. 10, pp. 3296–3304, 2021, doi: <a href="https://doi.org/10.1111/ajt.16731">10.1111/ajt.16731</a>.</div>
</div>
<div id="ref-gongEstimatingAverageTreatment2017" class="csl-entry">
<div class="csl-left-margin">[79] </div><div class="csl-right-inline">Q. Gong and D. E. Schaubel, <span>“Estimating the average treatment effect on survival based on observational data and using partly conditional modeling,”</span> <em>Biometrics</em>, vol. 73, no. 1, pp. 134–144, 2017, doi: <a href="https://doi.org/10.1111/biom.12542">10.1111/biom.12542</a>.</div>
</div>
<div id="ref-whiteMultipleImputationUsing2011" class="csl-entry">
<div class="csl-left-margin">[80] </div><div class="csl-right-inline">I. R. White, P. Royston, and A. M. Wood, <span>“Multiple imputation using chained equations: Issues and guidance for practice,”</span> <em>Statistics in Medicine</em>, vol. 30, no. 4, pp. 377–399, 2011, doi: <a href="https://doi.org/10.1002/sim.4067">10.1002/sim.4067</a>.</div>
</div>
<div id="ref-nephewExceptionPointsBody2017" class="csl-entry">
<div class="csl-left-margin">[81] </div><div class="csl-right-inline">L. D. Nephew, D. S. Goldberg, J. D. Lewis, P. Abt, M. Bryan, and K. A. Forde, <span>“Exception points and body size contribute to gender disparity in liver transplantation,”</span> <em>Clinical Gastroenterology and Hepatology</em>, vol. 15, no. 8, pp. 1286–1293.e2, 2017, doi: <a href="https://doi.org/10.1016/j.cgh.2017.02.033">10.1016/j.cgh.2017.02.033</a>.</div>
</div>
<div id="ref-kwongOPTNSRTR20202022" class="csl-entry">
<div class="csl-left-margin">[82] </div><div class="csl-right-inline">A. J. Kwong <em>et al.</em>, <span>“<span>OPTN/SRTR</span> 2020 <span>Annual Data Report</span>: <span>Liver</span>,”</span> <em>American Journal of Transplantation</em>, vol. 22, no. S2, pp. 204–309, 2022, doi: <a href="https://doi.org/10.1111/ajt.16978">10.1111/ajt.16978</a>.</div>
</div>
<div id="ref-bernardsAwardingAdditionalMELD2022" class="csl-entry">
<div class="csl-left-margin">[83] </div><div class="csl-right-inline">S. Bernards <em>et al.</em>, <span>“Awarding additional <span>MELD</span> points to the shortest waitlist candidates improves sex disparity in access to liver transplant in the <span>United States</span>,”</span> <em>American Journal of Transplantation</em>, vol. 22, no. 12, pp. 2912–2920, 2022, doi: <a href="https://doi.org/10.1111/ajt.17159">10.1111/ajt.17159</a>.</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="CHdynremeld.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="CHelassimulator.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["thesis.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
